Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-03

FDA Approved: LEVETIRACETAM IN SODIUM CHLORIDE — Supplemental Application (Nexus Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for levetiracetam in sodium chloride from Nexus Pharmaceuticals LLC to market a generic injectable formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levetiracetam in Sodium Chloride (LEVETIRACETAM IN SODIUM CHLORIDE)

Snippet

SUPPL AP for LEVETIRACETAM IN SODIUM CHLORIDE (LEVETIRACETAM)